

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

Genomewide association study of epiretinal membrane: discovery of significant risk loci in each of three American populations

Short title: GWAS of Epiretinal Membrane in Multiple Populations

Joel Gelernter (1,2,3, *), Daniel Levey (1,2), Marco Galimberti (1,2), Kelly Harrington (4,5), Hang Zhou (1,2), Keyrun Adhikari (1,2), J. Michael Gaziano (6,7), Dean Elliott (8), and Murray B. Stein (9,10)

1. Department of Psychiatry, Yale School of Medicine, New Haven, CT.
2. Department of Psychiatry, VA Connecticut Healthcare Center, West Haven, CT.
3. Departments of Genetics and Neuroscience, Yale School of Medicine, New Haven, CT.
4. Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA.
5. Department of Psychiatry, Boston University Chobanian & Avedisian School of Medicine, , Boston, MA.
6. Department of Medicine, Harvard Medical School, Boston, MA.
7. Department of Medicine, Divisions of Aging and Preventative Medicine, Brigham and Women’s Hospital, Boston, MA.
8. Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA.
9. University of California, San Diego, La Jolla, CA.
10. VA San Diego Healthcare System, San Diego, CA.

**Correspondence*

Joel Gelernter,
Department of Psychiatry,
Division of Human Genetics
Yale University School of Medicine,
VA CT Healthcare Center
West Haven, CT 06516.
joel.gelernter@yale.edu.

46 **Abstract**

47 **IMPORTANCE:** Epiretinal membrane (ERM) is a common retinal condition characterized by the presence
48 of fibrocellular tissue on the retinal surface, often with consequent loss of vision and visual distortion.

49 **OBJECTIVE:** Genomewide association studies (GWAS) can reveal the biology underlying complex genetic
50 traits like ERM; there have been no previous large-scale GWAS of this trait.

51 **DESIGN:** We used electronic health record diagnosis to identify Million Veteran Program (MVP)
52 participants with ERM in three populations for genomewide association analysis and further statistical
53 investigation of the results.

54 **SETTING:** Veterans who volunteered for the nationwide Department of Veterans Affairs MVP study,
55 eligible because they have used Veterans Health Administration facilities

56 **PARTICIPANTS:** 31,374 European-American (EUR) cases and 414,052 EUR controls, 4,739 African-
57 American (AFR) cases and 107,773 AFR controls, and 2,119 Latino (Admixed American, AMR) cases and
58 36,163 AMR controls – a total of 38,232 cases and 557,988 controls.

59 **METHODS:** We completed GWAS in each population separately, then results were meta-analyzed. We
60 also evaluated genetic correlation with other traits in external samples, and completed pathway
61 enrichment analyses.

62 **MAIN OUTCOME MEASURES:** Genomewide-significant association with ERM.

63 **RESULTS:** Genomewide significant associations were observed in all three populations studied: 31 risk
64 loci in EUR subjects, 3 in AFR, and 2 in AMR, with 48 identified in trans-ancestry meta-analysis. The most
65 strongly associated locus in both EUR (*rs9823832*, $p=9.06 \times 10^{-37}$) and the meta-analysis (*rs28630834*,
66 $p=2.90 \times 10^{-37}$) was *DHX36* (DEAH-Box Helicase 36). We investigated expression quantitative trait locus
67 associations for eye related function and found several GWS variants associate to alterations in gene
68 expression in the macula, including *DHX36***rs9438*. ERM showed significant genetic correlation to

69 depression and to disorders of the vitreous. Pathway enrichment analyses implicated collagen and
70 collagen-adjacent mechanisms, among others.

71 **CONCLUSIONS AND RELEVANCE:** This well-powered ERM GWAS has identified novel genetic
72 associations, some very strong, that point to biological mechanisms for ERM and merit further
73 investigation.

74

75 Keywords: Million Veteran Program (MVP), genomewide association study (GWAS), epiretinal
76 membrane (ERM), macular pucker, multi-ancestry study, transcriptome wide association study (TWAS),
77 pleiotropy

78

79

80 **Introduction**

81 Epiretinal membrane (ERM), sometimes called macular pucker, is characterized by the proliferation of
82 cells on the retinal surface. These cells adhere to the retina, produce extracellular matrix, and develop
83 contractile properties, resulting in tangential retinal traction and distortion of the retinal architecture.
84 Symptoms can be severe and require surgery; patients may complain of loss of central vision and/or
85 visual distortion (metamorphopsia, “wavy vision”). Diagnosis can be established by ophthalmoscopy,
86 fundus photography, and optical coherence tomography (OCT). It is common, with prevalence of 2% in
87 patients age >50 and 20% age >75. Age is associated with increased risk, and smoking may be associated
88 with decreased risk¹. The most common cause is posterior vitreous detachment, an age-related
89 separation of the vitreous from the retina. Most patients do not require intervention; for those with
90 symptomatic ERM, vitrectomy with epiretinal membrane peeling is the typical treatment and results are
91 variable; there is no nonsurgical treatment. While many of the pathophysiological processes that lead to
92 ERM are known and there is considerable knowledge of its biology², the underlying molecular genetic
93 risk factors are not understood.

94
95 Genomewide association studies (GWAS) are presently the most useful, and most universally applicable,
96 tools to understand the biology underlying genetically complex traits such as ERM. Large GWAS have
97 been previously performed to identify common variant associations with defects related to the macula,
98 but these have focused mostly on age-related macular degeneration (AMD)³ (including the first major
99 GWAS⁴.) A GWAS study in the UK Biobank considered AMD, diabetic retinopathy, retinal detachment,
100 glaucoma, and myopia, with risk loci mapped for each trait and pleiotropy between them⁵. A large
101 GWAS of cataract in UK Biobank⁶, Genetic Epidemiology Research on Adult Health and Aging (GERA)⁷,
102 and 23andme (a personal genomics company) reported 54 genomewide significant (GWS) risk loci. ERM,

103 though, has, to our knowledge, not been studied with respect to genetics using any genomewide
104 approach.

105
106 To identify a large number of risk genes, novel biology, and phenotypic subtypes, GWAS with large
107 sample size are necessary. The Department of Veterans Affairs (VA) Million Veteran Program (MVP) is
108 one of the world's largest biobanks including genetic, environmental, and medical information, based on
109 data from United States military veterans.⁸⁻¹¹ The MVP has enrolled >900,000 participants, with
110 excellent representation from non-European-ancestry participants. Genotype data are currently
111 available for >650,000 participants. The MVP sample is relatively old (55% are between ages 50-69¹⁰)
112 and ill – subjects are enrolled based on their use of the US Veterans Health Administration system. We
113 conducted a GWAS of ERM in the MVP sample, using diagnoses based on the electronic health record
114 (EHR).

115

116

117 **Subjects and Methods**

118 **MVP: Primary analyses**

119 We used data release version 4 of the MVP.¹² Linked and de-identified EHRs were queried using the
120 Veterans Affairs Informatics and Computing Infrastructure to identify individuals with International
121 Classification of Disease (ICD) codes for ERM, specified in the Supplementary Methods. These codes
122 identified 31,374 European-American (EUR) cases and 414,052 EUR controls, 4,739 African-American
123 (AFR) cases and 107,773 AFR controls, and 2,119 AMR (Admixed American or Latino) cases and 36,163
124 AMR controls; more detail is provided in Table 1. Research involving the MVP in general is approved by
125 the VA Central Institutional Review Board. All participants provided written informed consent.

126

127 **FinnGen: Phenotypes for pleiotropy analyses**

128 We accessed GWAS summary statistics from FinnGen¹³, a Finnish nationwide biobank collection, data
129 freeze version 7, for two traits potentially relating to ERM, “diseases of the vitreous body” and
130 “glaucoma”. ICD-10 codes used for diagnosis definition, Supplementary Methods.

131

132 *Genotyping, Imputation, Quality Control (QC), and GWAS*

133 Genotyping and imputation of MVP subjects has been described previously.^{10,14} Briefly, a customized
134 Affymetrix Axiom Array was used for genotyping. MVP genotype data for biallelic SNPs were imputed
135 using Minimac4 and a reference panel from the African Genome Resources (AGR) by the Sanger
136 Institute. Details, Supplement.

137

138 For the FinnGen dataset¹³, results were downloaded from the FinnGen website after registration
139 (https://www.finngen.fi/en/access_results). Analyses details are given in the Supplement.

140

141

142 Heritability and Genetic correlations

143 Linkage disequilibrium score regression (LDSC)¹⁵ was used to calculate liability scale SNP-heritability for
144 EUR, AFR and AMR ancestry of MVP data for ERM. We used a value of 0.091 for the population
145 prevalence¹. For EUR, this was calculated directly with LDSC. To estimate liability scale SNP-heritability
146 for AFR and AMR cohorts, we calculated LD scores with cov-LDSC¹⁶ from 10,000 random independent
147 individuals for the SNPs identified in the HapMap Project¹⁷. LDSC was also used to calculate genetic
148 correlation¹⁸ between the EUR MVP data for ERM and four other traits: two ophthalmologic traits,
149 glaucoma¹⁹ and disorders of the vitreous body¹³; and two psychiatric traits, posttraumatic stress
150 disorder (PTSD)²⁰ and depression²¹.

151

152 Cross-ancestry Fine-mapping

153 We did fine-mapping leveraging LD information from multiple ancestries to identify potential causal
154 variants using MsCAVIAR²². Details, Supplement.

155

156 Expression QTLs (eQTL)

157 GWAS significant loci were investigated to determine whether they were eQTLs using an eye tissue
158 specific database²³. Lead variants from the EUR ancestry GWAS were looked up first; if lead variants
159 were not available proxy SNPs were selected from genomewide significant (GWS) variants in the same
160 locus.

161

162 Transcriptome-Wide Association Study (TWAS) and Fine-mapping

163 We performed TWAS using FUSION²⁴ for the EUR GWAS statistics. Details, Supplement.

164

165 MAGMA gene-based and gene set analyses

166 We used MAGMA²⁵ implemented in FUMA²⁶ for gene-based and gene-set analyses. Details,

167 Supplement.

168

169

170 **Results**

171 MVP analyses

172 GWS associations were observed in all three populations studied. 31 risk loci were identified in EUR
173 subjects, 3 in AFR, and 2 in AMR, reflecting the greater power of the analysis in EUR compared to the
174 other two populations presumably due to difference in sample sizes (Table 2a-c; Figures S1-S3).

175
176 In EUR, of the 31 GWS loci, 14 were associated with a p-value $<10^{-10}$. The most strongly supported
177 variant was rs9823832 ($p=9.06 \times 10^{-37}$) which maps to *DHX36* (DEAH-Box Helicase 36). Other associated
178 variants highlighted for biological interest (Discussion) include *CPLX4* (rs7244528 associated at 2.84×10^{-22}),
179 *ROBO3*, to which variant rs10893291 maps (associated at 6.12×10^{-17}), and rs1011400 at locus *ABLIM3*
180 ($p=2.87 \times 10^{-14}$). Additional associated loci include *FTO**rs17817964 ($p=3.04 \times 10^{-11}$) (FTO Alpha-
181 Ketoglutarate Dependent Dioxygenase) and *RARB**rs57281891 ($p=1.13 \times 10^{-10}$) (Retinoic Acid Receptor
182 Beta). Other associated variants map to *CDKN2B-AS1* (rs10120688, $p=8.35 \times 10^{-19}$) and *ACOXL* – two
183 independent variants $>115,000$ basepairs apart, rs6731210 ($p=5.93 \times 10^{-18}$) and rs114671763 ($p=1.13 \times 10^{-11}$).
184 In AMR, the most strongly associated locus ($p=2.21 \times 10^{-9}$) was *CHRM2**rs7801770, which encodes
185 Cholinergic Receptor Muscarinic 2. (This *CHRM2* SNP is not polymorphic in EUR and non-significant in
186 AFR ($p=0.44$).)

187
188 The trans-ancestry meta-analysis identified 48 GWS variants (Figure 1, Table 3); many were not
189 significant (at $p \leq 5 \times 10^{-8}$) in any of the population-specific analyses. Of these 48 variants, 27 regions had
190 p-value stronger than 10^{-10} . In numerous cases, the same gene was implicated in the meta-analysis as
191 for EUR but with a different lead variant; the same variant as for EUR-only and meta-analysis was
192 implicated in 15 instances (Table 3). In the trans-ancestry meta-analysis, the most strongly supported
193 variant maps to *DHX36* as for EUR – a different variant at the same risk locus, rs28630834 ($p=2.90 \times 10^{-37}$).

194 The only variant that was GWS in more than one population was *RNU6ATAC21P** rs34825161 (RNA,
195 U6atac Small Nuclear 21, Pseudogene), significant in EUR ($p=2.15 \times 10^{-18}$), AFR ($p=1.84 \times 10^{-8}$), and also the
196 trans-ancestry meta ($p=3.88 \times 10^{-24}$). The other variants identified in AFR and AMR may be population-
197 specific.

198

199 Heritability and Genetic correlations

200 The LDSC analysis showed significant heritability for EUR ERM ($h^2=0.050 \pm 0.006$; $p=3.41 \times 10^{-15}$) and
201 demonstrated significant positive genetic correlation (r_g) between ERM and disorders of the vitreous
202 body ($r_g=0.25 \pm 0.087$; $p=0.39 \times 10^{-2}$), and depression ($r_g=0.14 \pm 0.039$; $p=0.04 \times 10^{-2}$), whereas the genetic
203 correlations between ERM and glaucoma and PTSD were not significant ($r_g=0.007 \pm 0.063$, $p=0.92$;
204 $r_g=0.080 \pm 0.057$; $p=0.16$). The Manhattan plot for the GWAS on “disorders of the vitreous body” is
205 provided in Figure S4. We also observed significant heritability in AFR ($h^2=0.064 \pm 0.031$; $p=0.039$) but we
206 obtained a non-significant heritability for AMR ($h^2=0.021 \pm 0.050$; $p=0.67$). Due to lack of power and
207 comparators, it was not possible to examine genetic correlations in these latter two populations.

208

209 Cross-ancestry Fine-mapping for potential causal variants

210 We performed fine-mapping to identify potential causal variants in 33 loci identified by the cross-
211 ancestry meta-analysis (Table S1). The median number of SNPs in the credible sets was 7. Six credible
212 sets contain only a single variant with PIP $\geq 99\%$ which could be targets for follow-up studies, including
213 rs114671763, rs34825161, rs76152172, rs6477779, rs8094635 and rs117896793. There are 18 credible
214 sets with ≤ 5 variants.

215

216 Associated variants' influence on gene expression

217 Two lead variants from the EUR GWAS were significantly associated with gene expression changes in the
218 eye, rs1011400 and rs4245808 (Figure 2). Rs1011400 was significantly associated with changes in
219 antisense RNA transcript *AC012613.2* in both macula ($p=5.43 \times 10^{-16}$, $FDR=2.78 \times 10^{-12}$) and non-macula
220 retinal tissue ($p=6.48 \times 10^{-12}$, $FDR=1.75 \times 10^{-8}$). Rs1011400 was also significantly associated with changes in
221 macula *ABLIM3* ($p=1.22 \times 10^{-4}$, $FDR=0.036$) expression. Rs4245808 was significantly associated with non-
222 macular retinal pigment epithelium expression of *AC073283.1* ($p=2.86 \times 10^{-5}$, $FDR=0.017$). Three
223 additional GWS proxy variants were associated with eye gene expression changes: rs2416908 (proxy for
224 rs4838069) was associated with expression changes in *DENND1A* (the gene encoding DENN Domain
225 Containing 1A) in macular retinal pigment epithelium ($p=6.24 \times 10^{-5}$, $FDR=0.036$), rs803141 (proxy for
226 rs2277066) with *CCNI2* (encoding Cyclin I Family Member 2; $p=1.14 \times 10^{-8}$, $FDR=2.26 \times 10^{-5}$) and *SEPT8*
227 (encoding Septin 8; $p=3.00 \times 10^{-5}$, $FDR=0.018$) in non-macular retinal pigment epithelium, and rs9438
228 (proxy for rs9823832) with *DHX36* in the macula ($p=2.80 \times 10^{-5}$, $FDR=0.011$).

229
230
231

232 Transcriptome-Wide Association Study (TWAS) and Fine-mapping

233 TWAS identified 28 independent associated genes (Table S2). The most significant gene was *DDX50P2* in
234 testis ($p=0.92 \times 10^{-24}$), a pseudogene, followed by *CDKN2A* ($p=0.29 \times 10^{-17}$) in the brain cortex.

235

236 For TWAS fine-mapping, we obtained 12 genes with posterior inclusion probability (PIP) ≥ 0.9 , and 7
237 more genes with PIP ≥ 0.7 (Table S3). Four genes had the highest PIP value (PIP=1): *CRIP1*, *MUSK*,
238 *DDX50P2*, and *MALT1*.

239

240 MAGMA gene-based and gene set analyses

241 MAGMA gene-based analysis provided a list of 25 significant genes which survived Bonferroni correction
242 ($p < 2.62 \times 10^{-6}$); these were provided as input for the gene set enrichment analysis (Table S4).

243 We obtained one significant term, the curated gene set of vitamin C in brain (Beta=1.296, STD=0.027,
244 SE=0.282, $p=2.12 \times 10^{-6}$, $P_{\text{bon}}=0.033$).

245

246 Functional Enrichment Analysis

247 There were significant enrichment results with six GO pathways (cyclin-dependent protein
248 serine/threonine kinase inhibitor activity, collagen type IV trimer, networking-forming collagen trimer,
249 collagen network, basement membrane collagen trimer, and complex of collagen trimers), and two
250 significant protein complexes (CycD–Cdk4 and IL4-IL4R) (Table S4).

251

252

253 **Discussion**

254 In this first well-powered GWAS of ERM conducted in the MVP, we identified 31 independent GWS risk
255 loci in EUR participants, 3 independent loci in AFR, and 2 in AMR. In the trans-ancestry meta-analysis, 48
256 independent risk loci were identified. This trait is very important clinically – it is the most common
257 retinal disease in adults²⁷ -- and it causes substantial morbidity.

258
259 The most strongly supported variant in EUR was rs9823832 ($p=9.06 \times 10^{-37}$), at *DHX36* (DEAH-Box Helicase
260 36). In the trans-ancestry meta-analysis, the most strongly supported variant also maps to *DHX36* – a
261 different variant at the same locus, rs28630834 ($p=2.90 \times 10^{-37}$). We did not identify any previous
262 association of this locus to an ocular phenotype, but its relevance is supported by follow-up analysis that
263 found that a GWS SNP in this locus (rs9438, $p=6.38 \times 10^{-13}$) alters expression of *DHX36* in macula (Figure
264 2). Considering some of the other associated variants of immediate biological interest in EUR, the
265 protein product of *CPLX4* (rs7244528, $p=2.84 \times 10^{-22}$) plays a role in photoreceptor ribbon synapses^{28,29}.
266 *ROBO3*, to which variant rs10893291 maps ($p=6.12 \times 10^{-17}$), encodes Roundabout Guidance Receptor 3,
267 involved in axonal navigation³⁰. Rs1011400 maps to *ABLIM3* ($p=2.87 \times 10^{-14}$), which encodes an actin-
268 binding protein related to nervous system development, previously reported to be associated to
269 macular thickness³¹. We noted that variation at this locus alters expression in the macula of *ABLIM3* and
270 *AC012613.2*. *FTO**rs17817964 ($p=3.04 \times 10^{-11}$) represents a locus well known for associations to body
271 mass index-related traits. *RARB**rs57281891 ($p=1.13 \times 10^{-10}$) maps to the locus that encodes Retinoic Acid
272 Receptor Beta, which binds retinoic acid. This locus has been previously associated to optic disc area³².
273 Rs10120688 (*CDKN2B-AS1*) has been associated to primary open-angle glaucoma (POAG)³³. *LPAR1*, the
274 second-most-strongly associated locus both in EUR ($p=1.81 \times 10^{-26}$) and in the trans-ancestry meta-
275 analysis ($p=2.34 \times 10^{-26}$) (different SNPs) encodes lysophosphatidic acid receptor 1. The protein product is

276 a G-protein coupled receptor with a range of biological functions implicated in several traits with
277 variants associated to eosinophil count³⁴, and central corneal thickness³⁵.

278

279

280 Other associated variants are linked to a range of different biological functions, e.g. two independent
281 variants map to *ACOXL* (Acyl-Coenzyme A Oxidase-Like Protein), (rs6731210, $p=5.93 \times 10^{-18}$; rs114671763,
282 $p=1.13 \times 10^{-11}$; fine-mapping revealed it is a potential causal variant with PIP >0.99) – this locus was
283 previously associated to chronic lymphocytic leukemia³⁶.

284

285 In AMR, the most strongly associated locus ($p=2.21 \times 10^{-9}$) was *CHRM2*, which encodes Cholinergic
286 Receptor Muscarinic 2. Atropine, a mydriatic, is an agonist at the protein product of *CHRM2*, as is
287 carbamoylcholine, an anti-glaucoma agent. Different variants at this locus have been shown to be
288 associated to resting heart rate response to recovery after exercise³⁷ and to risk-taking behavior³⁸,
289 among other phenotypes. Considering the association with ERM and *CHRM2* observed in AMR as well as
290 *CDKN2B-AS1* (previously POAG-associated) in EUR, we explored the relationship of ERM and glaucoma
291 further, but the genetic correlation between ERM and glaucoma was not significant; clinically, these
292 traits (ERM and glaucoma) are not considered to be associated. LDSC was feasible only in EUR, and it is
293 possible that this lack of a significant genetic correlation between these traits reflects an AMR-specific
294 genetic relationship -- the lead *CHRM2* variant was monomorphic in EUR and not significant in AFR.
295 However, there were significant genetic correlations between ERM and two other traits evaluated,
296 depression and disorders of the vitreous (the latter from a FinnGen analysis). Visual impairment has
297 been reported previously to be associated with increases in depression^{39,40}. ERM is related to vitreous
298 pathology, and risk is increased by vitreous detachment²⁷.

299

300 The trans-ancestry meta-analysis identified 48 GWS variants, many not observed in any of the
301 population-specific analyses. In numerous cases, the same gene was implicated but with a different lead
302 variant, supporting shared biology between populations (Table 3). The only variant that was GWS in
303 more than one population was *RNU6ATAC21P**rs34825161 (RNA, U6atac Small Nuclear 21,
304 Pseudogene), significant in EUR, AFR, and the trans-ancestry meta-analysis. The other variants identified
305 in AFR and AMR were not GWS in the meta-analysis, and these associations may be population-specific.
306
307 *CRIPT*, one of the genes identified by TWAS, encodes the Cysteine-Rich PDZ-Binding Protein, and high
308 myopia is among several clinical traits associated with variants at this locus in a patient with an exon 1
309 deletion⁴¹. Another TWAS-associated gene, *CDKN2B-AS1*, which encodes Cyclin Dependent Kinase
310 Inhibitor 2A, is associated with POAG, as noted above, and with several melanoma subtypes⁴². The
311 protein product of *MUSK*, Muscle Associated Receptor Tyrosine Kinase, has been implicated in clustering
312 of postsynaptic acetylcholine receptors in neuromuscular junction⁴³ – interesting in the context of the
313 *CHRM2* (Cholinergic Receptor Muscarinic 2) SNP-based association discussed above.
314
315 Pathway enrichment analysis using two different approaches revealed significant findings for collagen
316 and for the collagen-adjacent vitamin C pathway. Vitamin C (ascorbic acid) is necessary for the
317 hydroxylation of the proline residue in collagen, necessary to stabilize collagen fibers⁴⁴; MAGMA gene
318 set enrichment analysis implicated vitamin C brain pathways. Collagen is a major constituent of
319 epiretinal membranes, varying depending on the kind of membrane⁴⁵ and a proteomic study has
320 demonstrated that some collagens are upregulated in ERM⁴⁶. Collagen type I and type IV are the two
321 primary collagens founded in corneal and lens tissues; ⁴⁷ g:profiler implicated collagen type IV trimer,
322 network-forming collagen trimer, collagen network, basement membrane collagen trimer, and complex
323 of collagen trimer (Table S4).

324
325 Above we highlight biology mostly consistent with prior knowledge, but our results also implicate more
326 peripherally-connected biology. *FOXL1*, for example, encodes forkhead box L1. The same variant at this
327 locus (rs1019574) is strongly associated to ERM in both EUR and the trans-population meta-analysis.
328 Prior associations at this locus relate to, for example, bone mineral density⁴⁸ and height⁴⁹. It is also
329 involved in eye development⁵⁰, but may implicate a novel mechanism in the context of ERM.

330
331 Non-European populations are generally understudied with respect to GWAS. Since many genetic
332 findings are at least to some extent population-specific, this is a major limitation that needs to be
333 addressed by the research field as a whole⁵¹. For personalized medicine to become an effective strategy,
334 population-specific polygenic risk scores will generally need to be available for each clinical population
335 where a need for risk prediction is anticipated. This study demonstrates the strength of the MVP sample
336 in addressing this issue, as we were able to study reasonable sample sizes of three major populations.
337 Our findings contain a suggestion of some population-specific biology for ERM.

338
339 Our work has several limitations. ERM is diagnosed reliably via optical coherence tomography⁵² (OCT).
340 Diagnoses recorded in the electronic health record (EHR) may reflect clinical or OCT diagnosis, but with
341 large sample sizes signal overwhelms noise, tending to compensate for diagnosis imprecision. It is a
342 limitation that we relied on EHR-based diagnosis and might have included secondary ERM cases. In
343 relying on chart diagnosis that reflect the skills of a wide range of individual clinicians, it is likely that we
344 included some false-positive amongst the cases with non-ERM pathology. However EHR diagnoses have
345 been used widely and with great success previously for diagnosis of complex genetic traits (such as, for
346 example, major depressive disorder⁵³ and opioid use disorder⁵⁴ specifically in the MVP), and the
347 convergence of the identified risk loci identified with what is known about the pathophysiology of the

348 disorder, supports that they are likely to be relevant to ERM. A further limitation is the mostly-male
349 composition of the MVP sample; there may be sex-specific risk factors that we could not evaluate.

350

351 We identified GWS-significant associations to ERM in EUR, AFR, and AMR each taken individually, and
352 many more GWS-associations in the trans-ancestry meta-analysis. Results from pathway enrichment
353 analyses were consistent with known ERM pathophysiology. Availability of these genomewide results
354 will enable the creation of polygenic risk scores (PRS) expected to be predictive of genetic risk for ERM.
355 These findings should lead to improved understanding of the pathophysiology of ERM and, ideally,
356 identifications of new targets for nonsurgical treatment interventions.

357

358 **Competing Interests**

359 Dr. Gelernter is named as an inventor on PCT patent application #15/878,640 entitled: "Genotype-
360 guided dosing of opioid agonists," filed January 24, 2018 and issued on January 26, 2021 as U.S. Patent
361 No. 10,900,082. Dr. Gelernter is paid for editorial work for the journal "Complex Psychiatry" (Karger).
362 Dr. Eliot is ad hoc consultant for Alcon, Dutch Ophthalmic, GelMEDIX, and Genentech; reports research
363 funding from Neurotech and Unity Biotechnology; is a member of the Advisory Board & Stockholder for
364 InGel Therapeutics, Pykus Therapeutics, and RetMap; reports being Advisor, Patents, Royalties, and
365 Stockholder in Aldeyra Therapeutics; and is a member of the Data Safety Monitoring Board (DSMB) for
366 Asclepix

367
368 Dr. Stein has in the past 3 years received consulting income from Acadia Pharmaceuticals, Aptinyx, atai
369 Life Sciences, BigHealth, Bionomics, BioXcel Therapeutics, Boehringer Ingelheim, Clexio, Eisai,
370 EmpowerPharm, Engrail Therapeutics, Janssen, Jazz Pharmaceuticals, NeuroTrauma Sciences, PureTech
371 Health, Sumitomo Pharma, and Roche/Genentech. Dr. Stein has stock options in Oxeia
372 Biopharmaceuticals and EpiVario. He has been paid for his editorial work on *Depression and Anxiety*
373 (Editor-in-Chief), *Biological Psychiatry* (Deputy Editor), and *UpToDate* (Co-Editor-in-Chief for Psychiatry).
374 He is on the scientific advisory board for the Brain and Behavior Research Foundation and the Anxiety
375 and Depression Association of America.

376

377 The other authors all report that they have no competing interests.

378

379

380 **Acknowledgments**

381 This research is based on data from the Million Veteran Program (MVP), Office of Research and
382 Development, Veterans Health Administration, and was supported by the MVP and the Veterans Affairs
383 Cooperative Studies Program study No. 575B. This work was also supported funding from the
384 Department of Veterans Affairs Office of Research and Development grants I01CX001849 – MVP025.
385 D.F.L. was supported by a was supported by an NARSAD Young Investigator Grant from the Brain &
386 Behavior Research Foundation and a Career Development Award CDA-2 from the Veterans Affairs Office
387 of Research and Development (1IK2BX005058-01A2) and is Aimee Mann Fellow of Psychiatric Genetics.
388 This publication does not represent the views of the Department of Veterans Affairs or the United States
389 Government. We also acknowledge the participants and investigators of the FinnGen study.

390

391 **Author contributions**

392 JG conceived the study, drafted the article, and supervised the work. DL and MG analyzed the data and
393 contributed to drafting the article. HZ and KA contributed to the data analysis. KH contributed to the
394 phenotyping effort in the MVP sample. JG, MBS, and JMG provided administrative support. Additionally,
395 all authors (DL, MG, KH, HZ, KA, JMG, DE, and MBS) reviewed the article and provided critical comments.

396

397 **Data Availability**

398 Summary statistics will be made available in dbGAP (accession number phs001672) by the Million
399 Veteran Program following publication.

400

401

402

REFERENCES

- 403
404
- 405 1. Xiao W, Chen X, Yan W, Zhu Z, He M. Prevalence and risk factors of epiretinal membranes: a
406 systematic review and meta-analysis of population-based studies. *BMJ Open*.
407 2017;7(9):e014644.
 - 408 2. Bianchi L, Altera A, Barone V, et al. Untangling the Extracellular Matrix of Idiopathic Epiretinal
409 Membrane: A Path Winding among Structure, Interactomics and Translational Medicine. *Cells*.
410 2022;11(16).
 - 411 3. Fritsche LG, Igl W, Bailey JNC, et al. A large genome-wide association study of age-related
412 macular degeneration highlights contributions of rare and common variants. *Nature genetics*.
413 2016;48(2):134-143.
 - 414 4. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular
415 degeneration. *Science (New York, N.Y.)*. 2005;308(5720):385-389.
 - 416 5. Xue Z, Yuan J, Chen F, et al. Genome-wide association meta-analysis of 88,250 individuals
417 highlights pleiotropic mechanisms of five ocular diseases in UK Biobank. *EBioMedicine*.
418 2022;82:104161.
 - 419 6. Collins R. What makes UK Biobank special? *Lancet*. 2012;379(9822):1173-1174.
 - 420 7. Kvale MN, Hesselson S, Hoffmann TJ, et al. Genotyping Informatics and Quality Control for
421 100,000 Subjects in the Genetic Epidemiology Research on Adult Health and Aging (GERA)
422 Cohort. *Genetics*. 2015;200(4):1051-1060.
 - 423 8. Gelernter J, Sun N, Polimanti R, et al. Genome-wide association study of post-traumatic stress
424 disorder reexperiencing symptoms in >165,000 US veterans. *Nat Neurosci*. 2019;22(9):1394-
425 1401.
 - 426 9. Klarin D, Damrauer SM, Cho K, et al. Genetics of blood lipids among ~300,000 multi-ethnic
427 participants of the Million Veteran Program. *Nature genetics*. 2018.
 - 428 10. Gaziano JM, Concato J, Brophy M, et al. Million Veteran Program: A mega-biobank to study
429 genetic influences on health and disease. *Journal of clinical epidemiology*. 2016;70:214-223.
 - 430 11. Gaziano JM, Concato J, Galea S, Smith NL, Provenzale D. Epidemiologic approaches to veterans'
431 health. *Epidemiologic reviews*. 2015;37:1-6.
 - 432 12. Levey DF, Gelernter J, Polimanti R, et al. Reproducible Genetic Risk Loci for Anxiety: Results From
433 approximately 200,000 Participants in the Million Veteran Program. *Am J Psychiatry*.
434 2020;177(3):223-232.
 - 435 13. Kurki MI, Karjalainen J, Palta P, et al. FinnGen: Unique genetic insights from combining isolated
436 population and national health register data. *medRxiv*. 2022:2022.2003.22271360.
 - 437 14. Hunter-Zinck H, Shi Y, Li M, et al. Genotyping Array Design and Data Quality Control in the
438 Million Veteran Program. *American journal of human genetics*. 2020;106(4):535-548.
 - 439 15. Bulik-Sullivan BK, Loh PR, Finucane HK, et al. LD Score regression distinguishes confounding from
440 polygenicity in genome-wide association studies. *Nature genetics*. 2015;47(3):291-295.
 - 441 16. Luo Y, Li X, Wang X, et al. Estimating heritability and its enrichment in tissue-specific gene sets in
442 admixed populations. *Hum Mol Genet*. 2021;30(16):1521-1534.
 - 443 17. Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1
444 million SNPs. *Nature*. 2007;449(7164):851-861.
 - 445 18. Bulik-Sullivan B, Finucane HK, Anttila V, et al. An atlas of genetic correlations across human
446 diseases and traits. *Nature genetics*. 2015;47(11):1236-1241.
 - 447 19. Gharahkhani P, Jorgenson E, Hysi P, et al. Genome-wide meta-analysis identifies 127 open-angle
448 glaucoma loci with consistent effect across ancestries. *Nature communications*.
449 2021;12(1):1258.

- 450 20. Stein MB, Levey DF, Cheng Z, et al. Genome-wide association analyses of post-traumatic stress
451 disorder and its symptom subdomains in the Million Veteran Program. *Nature genetics*.
452 2021;53(2):174-184.
- 453 21. Levey DF, Stein MB, Wendt FR, et al. Bi-ancestral depression GWAS in the Million Veteran
454 Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. *Nat*
455 *Neurosci*. 2021;24(7):954-963.
- 456 22. LaPierre N, Taraszka K, Huang H, He R, Hormozdiari F, Eskin E. Identifying causal variants by fine
457 mapping across multiple studies. *PLoS genetics*. 2021;17(9):e1009733.
- 458 23. Orozco LD, Chen HH, Cox C, et al. Integration of eQTL and a Single-Cell Atlas in the Human Eye
459 Identifies Causal Genes for Age-Related Macular Degeneration. *Cell reports*. 2020;30(4):1246-
460 1259 e1246.
- 461 24. Gusev A, Ko A, Shi H, et al. Integrative approaches for large-scale transcriptome-wide association
462 studies. *Nature genetics*. 2016;48(3):245-252.
- 463 25. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: Generalized Gene-Set Analysis of
464 GWAS Data. *PLOS Computational Biology*. 2015;11(4):e1004219.
- 465 26. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of
466 genetic associations with FUMA. *Nature Communications*. 2017;8(1):1826.
- 467 27. Ota A, Tanaka Y, Toyoda F, et al. Relationship between variations in posterior vitreous
468 detachment and visual prognosis in idiopathic epiretinal membranes. *Clin Ophthalmol*.
469 2016;10:7-11.
- 470 28. Babai N, Sendelbeck A, Regus-Leidig H, et al. Functional Roles of Complexin 3 and Complexin 4 at
471 Mouse Photoreceptor Ribbon Synapses. *The Journal of neuroscience : the official journal of the*
472 *Society for Neuroscience*. 2016;36(25):6651-6667.
- 473 29. Vaithianathan T, Henry D, Akmentin W, Matthews G. Functional roles of complexin in
474 neurotransmitter release at ribbon synapses of mouse retinal bipolar neurons. *The Journal of*
475 *neuroscience : the official journal of the Society for Neuroscience*. 2015;35(9):4065-4070.
- 476 30. Jen JC, Chan WM, Bosley TM, et al. Mutations in a human ROBO gene disrupt hindbrain axon
477 pathway crossing and morphogenesis. *Science (New York, N.Y.)*. 2004;304(5676):1509-1513.
- 478 31. Gao XR, Huang H, Kim H. Genome-wide association analyses identify 139 loci associated with
479 macular thickness in the UK Biobank cohort. *Human molecular genetics*. 2019;28(7):1162-1172.
- 480 32. Springelkamp H, Mishra A, Hysi PG, et al. Meta-analysis of Genome-Wide Association Studies
481 Identifies Novel Loci Associated With Optic Disc Morphology. *Genetic epidemiology*.
482 2015;39(3):207-216.
- 483 33. Liu S, Chen S, Niu T. Genetic association between CDKN2B-AS1 polymorphisms and the
484 susceptibility of primary open-angle glaucoma (POAG): a meta-analysis from 21,775 subjects. *Ir J*
485 *Med Sci*. 2022;191(5):2385-2392.
- 486 34. Vuckovic D, Bao EL, Akbari P, et al. The Polygenic and Monogenic Basis of Blood Traits and
487 Diseases. *Cell*. 2020;182(5):1214-1231 e1211.
- 488 35. Iglesias AI, Mishra A, Vitart V, et al. Cross-ancestry genome-wide association analysis of corneal
489 thickness strengthens link between complex and Mendelian eye diseases. *Nature*
490 *communications*. 2018;9(1):1864.
- 491 36. Berndt SI, Skibola CF, Joseph V, et al. Genome-wide association study identifies multiple risk loci
492 for chronic lymphocytic leukemia. *Nature genetics*. 2013;45(8):868-876.
- 493 37. Verweij N, van de Vegte YJ, van der Harst P. Genetic study links components of the autonomous
494 nervous system to heart-rate profile during exercise. *Nature communications*. 2018;9(1):898.
- 495 38. Karlsson Linnér R, Biroli P, Kong E, et al. Genome-wide association analyses of risk tolerance and
496 risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic
497 influences. *Nature genetics*. 2019;51(2):245-257.

- 498 39. Frank CR, Xiang X, Stagg BC, Ehrlich JR. Longitudinal Associations of Self-reported Vision
499 Impairment With Symptoms of Anxiety and Depression Among Older Adults in the United
500 States. *JAMA Ophthalmol.* 2019;137(7):793-800.
- 501 40. Zhao X, Liu W, Lu B, Zhu X, Zhou M, Sun X. Visual impairment and depression in China: a 7-year
502 follow-up study from national longitudinal surveys. *BMJ Open.* 2022;12(4):e055563.
- 503 41. Leduc MS, Niu Z, Bi W, et al. CRIPT exonic deletion and a novel missense mutation in a female
504 with short stature, dysmorphic features, microcephaly, and pigmentary abnormalities. *Am J Med
505 Genet A.* 2016;170(8):2206-2211.
- 506 42. Rossi M, Pellegrini C, Cardelli L, Ciciarelli V, Di Nardo L, Fagnoli MC. Familial Melanoma:
507 Diagnostic and Management Implications. *Dermatol Pract Concept.* 2019;9(1):10-16.
- 508 43. Tan-Sindhunata MB, Mathijssen IB, Smit M, et al. Identification of a Dutch founder mutation in
509 MUSK causing fetal akinesia deformation sequence. *European journal of human genetics : EJHG.*
510 2015;23(9):1151-1157.
- 511 44. Rappu P, Salo AM, Myllyharju J, Heino J. Role of prolyl hydroxylation in the molecular
512 interactions of collagens. *Essays Biochem.* 2019;63(3):325-335.
- 513 45. Kritzenberger M, Junglas B, Framme C, et al. Different collagen types define two types of
514 idiopathic epiretinal membranes. *Histopathology.* 2011;58(6):953-965.
- 515 46. Sun C, Zou H, Yang Z, et al. Proteomics and phosphoproteomics analysis of vitreous in idiopathic
516 epiretinal membrane patients. *Proteomics Clin Appl.* 2022;16(5):e2100128.
- 517 47. Song Y, Overmass M, Fan J, et al. Application of Collagen I and IV in Bioengineering Transparent
518 Ocular Tissues. *Frontiers in Surgery.* 2021;8.
- 519 48. Kim SK. Identification of 613 new loci associated with heel bone mineral density and a polygenic
520 risk score for bone mineral density, osteoporosis and fracture. *PLoS one.* 2018;13(7):e0200785.
- 521 49. Kichaev G, Bhatia G, Loh PR, et al. Leveraging Polygenic Functional Enrichment to Improve GWAS
522 Power. *American journal of human genetics.* 2019;104(1):65-75.
- 523 50. Nakada C, Satoh S, Tabata Y, Arai K, Watanabe S. Transcriptional repressor foxl1 regulates
524 central nervous system development by suppressing shh expression in zebra fish. *Mol Cell Biol.*
525 2006;26(19):7246-7257.
- 526 51. Sirugo G, Williams SM, Tishkoff SA. The Missing Diversity in Human Genetic Studies. *Cell.*
527 2019;177(4):1080.
- 528 52. Do DV, Cho M, Nguyen QD, et al. The impact of optical coherence tomography on surgical
529 decision making in epiretinal membrane and vitreomacular traction. *Trans Am Ophthalmol Soc.*
530 2006;104:161-166.
- 531 53. Levey DF, Stein MB, Wendt FR, et al. Bi-ancestral depression GWAS in the Million Veteran
532 Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. *Nat
533 Neurosci.* 2021;24(7):954-963.
- 534 54. Zhou H, Rentsch CT, Cheng Z, et al. Association of OPRM1 Functional Coding Variant With Opioid
535 Use Disorder: A Genome-Wide Association Study. *JAMA Psychiatry.* 2020.
- 536
- 537

538 Table 1: MVP sample demographic information.

539

EUR	Case	Control	Total
Male	30176	382566	412742
<i>Age (SEM)</i>	71.15(0.05)	64.22(0.02)	
Female	1198	31486	32684
<i>Age (SEM)</i>	64.78(0.78)	52.10(0.08)	
Total (EUR)	31374	414052	445426
AFR	Case	Control	Total
Male	4398	92592	96990
<i>Age (SEM)</i>	66.63(0.13)	58.66(0.04)	
Female	341	15181	15522
<i>Age (SEM)</i>	59.59(0.51)	48.75(0.09)	
Total (AFR)	4739	107773	112512
AMR	Case	Control	Total
Male	2055	32611	34666
<i>Age (SEM)</i>	68.25(0.20)	55.44(0.09)	
Female	64	3552	3616
<i>Age (SEM)</i>	62.4(0.91)	43.29(0.218)	
Total (AMR)	2119	36163	38282
TOTAL (All)	38232	557988	596220

540

541 Table 2: Independent significant risk loci identified in EUR, AFR, and AMR. A1, risk allele; FREQ,
542 frequency of A1 (sorted by p-value)

543 EUR ancestry:

544

Gene	HR	C	SNP	BP Hg19/GRCH37	A1	A2	FREQ	BETA	SE	P
<i>DHX36</i>	3		rs9823832	154024897	C	T	0.343906	-0.114203	0.00901605	9.06E-37
<i>LPAR1</i>	9		rs6477803	113792417	T	C	0.80847	-0.117122	0.011001	1.81E-26
<i>CPLX4</i>	8	1	rs7244528	56948972	A	T	0.700518	-0.089765	0.00924817	2.84E-22
<i>FOXL1</i>	6	1	rs1019574	86725801	A	G	0.525586	0.0764702	0.00861526	6.90E-19
<i>CDKN2B-AS1</i>	9		rs10120688	22056499	A	G	0.478935	-0.0759819	0.00858045	8.35E-19
<i>RNU6ATAC21P</i>	6		rs34825161	10185413	A	G	0.275068	-0.0859338	0.00982183	2.15E-18
<i>ACOXL</i>	2		rs6731210	112270857	T	C	0.600165	-0.0731687	0.00847459	5.93E-18
<i>ROBO3</i>	1	1	rs10893291	124705053	G	A	0.323993	-0.0758934	0.00907502	6.12E-17
<i>PLPP3</i>	1		rs9970807	56965664	T	C	0.0913253	-0.121161	0.0150691	8.96E-16
<i>ABLIM3</i>	5		rs1011400	148611941	C	G	0.438558	-0.0659999	0.00867952	2.87E-14
<i>HNF1B</i>	7	1	rs12601991	36101633	T	G	0.405415	0.0614149	0.00850638	5.21E-13
<i>ACOXL</i>	2		rs114671763	112154449	T	C	0.0940899	-0.101641	0.0149702	1.13E-11
<i>FTO</i>	6	1	rs17817964	53828066	T	C	0.393599	0.0569945	0.00857814	3.04E-11
<i>DENND1A</i>	9		rs4838069	126316511	T	C	0.172974	0.0739937	0.0111857	3.71E-11
<i>RARB</i>	3		rs57281891	25581866	C	CTT	0.133411	0.0803257	0.0124553	1.13E-10
<i>COL4A4</i>	2		rs6740108	227889559	C	A	0.414065	-0.0557971	0.00865244	1.13E-10
<i>LPAR1</i>	9		rs1279850	113972498	A	T	0.75331	-0.0613734	0.00957904	1.48E-10
<i>TP53</i>	7	1	rs78378222	7571752	G	T	0.0119663	0.221799	0.0354849	4.09E-10
<i>FOLH1</i>	1	1	rs10839258	49314465	G	A	0.229578	-0.0635619	0.0101969	4.56E-10
<i>OSTM1</i>	6		rs9480836	108458997	T	C	0.0729634	0.102286	0.0167332	9.81E-10
<i>SPNS3</i>	7	1	rs11285864	4354559	T	TC	0.603578	0.05319	0.00871949	1.06E-09
<i>LPAR1</i>	9		rs5899909	113410155	GAT	G	0.467903	-0.051705	0.00848558	1.11E-09
<i>BCR</i>	2	2	rs4822369	23516797	A	C	0.262917	0.0570984	0.00944604	1.50E-09
<i>EPAS1/PRKCE</i>	2		rs4245808	46456486	A	G	0.656504	0.0531805	0.00885061	1.87E-09
<i>UFL1</i>	6		rs530625467	96875349	G	C	0.0492389	0.145658	0.0252414	7.90E-09
<i>SOX10</i>	2	2	rs117896793	38381996	T	G	0.0269773	0.152644	0.0266889	1.07E-08
<i>DPF3</i>	4	1	rs4903064	73279420	C	T	0.240167	-0.0559642	0.00992863	1.73E-08

<i>CCNI2</i>	5	rs2277066	132072913	C	G	0.0839226	-0.0918094	0.0163619	2.01E-08
<i>DLL1</i>	6	rs7745573	170468193	C	A	0.426806	0.0477801	0.00860443	2.81E-08
<i>EIF3E</i>	8	rs7826090	109288442	G	A	0.233334	-0.0563344	0.0101514	2.87E-08
<i>HAS2</i>	8	rs279655	122803525	G	A	0.43985	-0.0472866	0.00853638	3.04E-08

545
546
547

AFR ancestry:

Gene	R	CH	SNP	BP Hg19/GRCH37	A1	A2	FREQ	BETA	SE	P
<i>RNU6ATAC21P</i>		6	rs34825161	10185413	A	G	0.130225	-0.210674	0.0374443	1.84088E-08
<i>NYAP2</i>		2	rs4675026	226889445	T	C	0.819976	-0.159703	0.0286954	2.61508E-08
<i>HSPA8</i>		11	rs14686788	122932732	A	C	0.00256511	0.918612	0.165897	3.07234E-08

548
549
550
551

AMR ancestry:

Gene	R	CH	SNP	BP Hg19/GRCH37	A1	A2	FREQ	BETA	SE	P
<i>CHRM2</i>		7	rs7801770	136494060	A	G	0.00514367	1.10126	0.184118	2.21E-09
<i>CAMTA1</i>		1	rs150631130	7705819	CGGCA	C	0.00525359	1.13444	0.199554	1.31E-08

552
553
554

555 Table 3. GWS variants identified in trans-ancestry meta.

556 **Bolded variants** indicate cases where an identical variant was identified in the EUR only GWAS (15/34).

557

Gene	CHR	SNP	Position	A1	A2	Freq.	Beta	SE	p-value	Directic (EUR ≠ AMR)
<i>DHX36</i>	3	rs28630834	154016838	A	G	0.6755	0.109	0.0085	2.90E-37	+++
<i>LPAR1</i>	9	rs4978978	113802433	C	G	0.1871	0.1077	0.0101	2.34E-26	+++
<i>CPLX4</i>	18	rs8094635	56948478	A	G	0.2823	0.0894	0.0086	3.56E-25	+++
<i>RNU6ATAC21P</i>	6	rs34825161	10185413	A	G	0.2625	-0.0943	0.0093	3.88E-24	---
<i>MIR4435-2HG</i>	2	rs200436484	112274727	C	G	0.5843	-0.0793	0.0084	3.35E-21	-?-
<i>FOXL1</i>	16	rs1019574	86725801	A	G	0.543	0.0713	0.0079	1.18E-19	+++
<i>CDKN2A-AS1</i>	9	rs10811645	22049656	A	G	0.5195	-0.0695	0.0077	1.90E-19	---
<i>ROBO3</i>	11	rs10893291	124705053	A	G	0.6821	0.0738	0.0083	4.83E-19	+++
<i>PPAP2B</i>	1	rs72664355	57007791	T	C	0.9176	0.1254	0.0157	1.46E-15	+++
<i>GPR149</i>	3	rs60572329	154085132	CG	C	0.8278	-0.0897	0.0115	6.64E-15	-?+
<i>ABLIM3</i>	5	rs1011400	148611941	C	G	0.4326	-0.0634	0.0084	5.57E-14	-?-
<i>HNF1B</i>	17	rs12601991	36101633	T	G	0.3906	0.0609	0.0083	2.42E-13	++?
<i>FTO</i>	16	rs17817964	53828066	T	C	0.3712	0.0586	0.0082	6.56E-13	+++
<i>ARHGEF26-AS1</i>	3	rs7617276	153776826	T	C	0.6435	0.0587	0.0082	6.86E-13	+++
<i>FOLH1</i>	11	rs2866349	49314336	T	G	0.7164	0.0633	0.009	2.00E-12	+++
<i>CTXN2</i>	15	rs2413887	48485926	T	C	0.652	0.1628	0.0232	2.37E-12	?++
<i>ACOXL</i>	2	rs114671763	112154449	T	C	0.0966	-0.0941	0.0136	4.00E-12	---
<i>COL4A4</i>	2	rs13393894	227880543	A	G	0.5635	0.0529	0.0078	1.46E-11	+++
<i>DENND1A</i>	9	rs4838069	126316511	T	C	0.1808	0.0725	0.0107	1.48E-11	+?+
<i>DPF3</i>	14	rs4903064	73279420	T	C	0.7632	0.0611	0.0091	1.98E-11	+++
<i>BCR</i>	22	rs5751598	23514450	A	G	0.7114	-0.0563	0.0084	2.05E-11	---
<i>TP53</i>	17	rs78378222	7571752	T	G	0.9885	-0.2296	0.0346	3.10E-11	---
<i>RARB</i>	3	rs1286767	25592883	T	C	0.8553	-0.073	0.011	3.16E-11	---
<i>OR2K2</i>	9	rs2773533	113980884	T	C	0.2802	0.0576	0.0087	3.17E-11	+++
<i>FOXL1</i>	16	rs71390846	86714715	C	G	0.1726	0.0687	0.0104	4.09E-11	+++
<i>SPNS3</i>	17	rs12601416	4357773	A	G	0.4094	-0.0526	0.008	4.33E-11	---
<i>LOC646813</i>	11	rs140544819	50366307	T	C	0.8979	0.0981	0.0151	7.27E-11	+?+
<i>EPAS1/PRKCE</i>	2	rs4245808	46456486	A	G	0.6642	0.0512	0.0081	2.38E-10	+++
<i>CCNI2</i>	5	rs2277066	132072913	C	G	0.0973	-0.0965	0.0154	3.27E-10	-?-


<i>OR4A5</i>	11	rs11246551	51419389	T	C	0.1264	-0.0764	0.0124	7.46E-10	---
<i>MUSK</i>	9	rs6477779	113392219	T	C	0.4991	-0.0476	0.0078	1.16E-09	--+
<i>OSTM1</i>	6	rs9480836	108458997	T	C	0.0724	0.0955	0.0157	1.27E-09	+++
<i>PTPRJ</i>	11	rs7130876	48050995	A	G	0.7947	0.0592	0.0098	1.34E-09	+++
<i>SOX10</i>	22	rs117896793	38381996	T	G	0.0265	0.1526	0.0255	2.10E-09	+++
<i>EIF3E</i>	8	rs7826090	109288442	A	G	0.7644	0.0569	0.0098	6.51E-09	+?+
<i>LIG1</i>	19	rs35844660	48655069	CCT	C	0.4915	-0.0478	0.0083	9.84E-09	-?-
<i>HAS2</i>	8	rs2581482	122801173	A	G	0.5411	0.0444	0.0078	1.04E-08	+++
<i>COL4A2</i>	13	rs9521744	111054827	A	T	0.3752	-0.0462	0.0081	1.16E-08	---
<i>DTWD1</i>	15	rs1976551	49923026	C	G	0.7572	0.1352	0.0239	1.45E-08	?++
<i>HNF1B</i>	17	rs34080163	36151146	A	G	0.1219	0.0646	0.0114	1.52E-08	+++
<i>TRIM48</i>	11	rs113285600	54857903	T	C	0.8795	0.0695	0.0124	2.15E-08	+++
<i>SH3PXD2A</i>	10	rs56149148	105508171	T	C	0.1177	0.0652	0.0117	2.54E-08	+++
<i>WVOX</i>	16	rs12928261	79041944	A	T	0.5727	-0.0446	0.008	2.74E-08	---
<i>SNAP23</i>	15	rs4923947	42791703	A	G	0.2234	0.1007	0.0182	3.01E-08	+++
<i>TPRX1</i>	19	rs12462705	48304700	A	G	0.4419	-0.0434	0.0079	3.54E-08	---
<i>HAS2</i>	8	rs529279493	122792069	T	C	0.9949	-0.4191	0.0761	3.59E-08	-??
<i>UFL1</i>	6	rs76152172	96907225	A	G	0.9477	-0.1158	0.021	3.66E-08	+-
<i>CDKN2A</i>	9	rs13288666	21973857	T	C	0.9563	0.1121	0.0204	3.99E-08	++-

558

559

560


561 Figure 1. Trans-ancestry meta-analysis Manhattan Plot.
562 Lead loci not identified in the European GWAS are highlighted.




563
564

565 Figure 2. eQTL results.

566 Expression QTLs were investigated in an eye tissue specific database. Lead SNPs were first looked up for
567 each locus, with 2 significant results after multiple testing correction (FDR<0.05): rs4245808 and
568 rs1011400. GWS proxy SNPs were selected when results were not available for the lead SNP, with three
569 additional SNPs showing significant eQTL (FDR<0.05): rs803141, rs2416908, and rs9438. Genotype is on
570 the X axis and Reads Per Kilobase Million (RPKM) is on the Y axis. Scale is variable and relative to the
571 transcript depicted in each figure.
572




573
574



575
576
577
578
579
580

Three overlapping genes showing eQTL with chr5 lead SNP rs1011400



581